COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
May 03, 2022 07:00 ET
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
April 20, 2022 07:00 ET
|
COMPASS Pathways
London, UK – 20 April 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Grow Therapy In-Network with Optum Nationally to Provide Members Access to High-Quality Mental Health Care
April 13, 2022 09:00 ET
|
Grow Therapy
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Grow Therapy, a leader in helping create life-changing therapeutic connections between therapists and clients, today announced its mental health care...
COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
March 24, 2022 05:00 ET
|
COMPASS Pathways
Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...
Grow Therapy Partners With Aetna To Take Its Mental Health Care Services Nationwide
March 17, 2022 09:00 ET
|
Grow Therapy
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Grow Therapy, a leader in helping create life-changing therapeutic connections between therapists and clients, today announced its mental health care...
Promises Behavioral Health Celebrates Third Annual Promise Week
February 07, 2022 10:03 ET
|
Promises Behavioral Health
Brentwood, Tenn., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Promises Behavioral Health, a quality provider of behavioral health services, celebrates its third annual Promise Week from February 7th to...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 19, 2022 07:00 ET
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
January 04, 2022 07:00 ET
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
COMPASS Pathways announces changes in Executive Team
December 16, 2021 07:40 ET
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 13, 2021 07:00 ET
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...